About: Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins
Creator	Hu, Chen-Yu Li, Lan-Juan Li, Yan-Hua Wu, Nan-Ping Yao, Hang-Ping
Source	Elsevier; Medline; PMC
abstract	Middle East respiratory syndrome (MERS) is a viral respiratory disease caused by a de novo coronavirus—MERS-CoV—that is associated with high mortality. However, the mechanism by which MERS-CoV infects humans remains unclear. To date, there is no effective vaccine or antibody for human immunity and treatment, other than the safety and tolerability of the fully human polyclonal Immunoglobulin G (IgG) antibody (SAB-301) as a putative therapeutic agent specific for MERS. Although rapid diagnostic and public health measures are currently being implemented, new cases of MERS-CoV infection are still being reported. Therefore, various effective measures should be taken to prevent the serious impact of similar epidemics in the future. Further investigation of the epidemiology and pathogenesis of the virus, as well as the development of effective therapeutic and prophylactic anti-MERS-CoV infections, is necessary. For this purpose, detailed information on MERS-CoV proteins is needed. In this review, we describe the major structural and nonstructural proteins of MERS-CoV and summarize different potential strategies for limiting the outbreak of MERS-CoV. The combination of computational biology and virology can accelerate the advanced design and development of effective peptide therapeutics against MERS-CoV. In summary, this review provides important information about the progress of the elimination of MERS, from prevention to treatment.
has issue date	2019-07-17(xsd:dateTime)
bibo:doi	10.1016/j.eng.2018.11.035
bibo:pmid	32288963
has license	no-cc
sha1sum (hex)	31c984803a0d9f243445e5ff6657edfc9ee5cde6
schema:url	https://doi.org/10.1016/j.eng.2018.11.035
resource representing a document's title	Molecular Characteristics, Functions, and Related Pathogenicity of MERS-CoV Proteins
has PubMed Central identifier	PMC7104727
has PubMed identifier	32288963
schema:publication	Engineering (Beijing)
resource representing a document's body	covid:31c984803a0d9f243445e5ff6657edfc9ee5cde6#body_text
is schema:about of	named entity 'PROTEINS' named entity 'prevent' named entity 'caused' named entity 'measures' named entity 'therapeutic' named entity 'specific' named entity 'prevention' named entity 'epidemics' named entity 'effective' named entity 'IgG' named entity 'Proteins' named entity 'PATHOGENICITY' named entity 'NECESSARY' named entity 'CAUSED BY' named entity 'ELIMINATION' named entity 'MIDDLE EAST RESPIRATORY SYNDROME ' named entity 'THERAPEUTIC AGENT' named entity 'FUTURE' named entity 'INFECTION' named entity 'INFORMATION' named entity 'SAFETY AND TOLERABILITY' named entity 'OTHER THAN' named entity 'POLYCLONAL' named entity 'SUMMARY' named entity 'SPECIFIC' named entity 'COMBINATION' named entity 'SIMILAR' named entity 'UNCLEAR' named entity 'STRUCTURAL' named entity 'ASSOCIATED WITH' named entity 'ACCELERATE' named entity 'DESIGN' named entity 'ADVANCED' named entity 'RESPIRATORY DISEASE' named entity 'COMPUTATIONAL BIOLOGY' named entity 'MORTALITY' named entity 'VIRAL' named entity 'MECHANISM' named entity 'CORONAVIRUS' named entity 'PROVIDES' named entity 'FUNCTIONS' named entity 'MERS-COV' named entity 'MOLECULAR' named entity 'CHARACTERISTICS' named entity 'RELATED' named entity 'TO PREVENT' named entity 'PEPTIDE' named entity 'INVESTIGATION' named entity 'EFFECTIVE' named entity 'ANTIBODY' named entity 'MERS' named entity 'MAJOR' named entity 'DEVELOPMENT' named entity 'PROGRESS' named entity 'IMPORTANT' named entity 'PURPOSE' named entity 'EPIDEMICS' named entity 'REPORTED' named entity 'HIGH' named entity 'TREATMENT' named entity 'NEEDED' named entity 'EPIDEMIOLOGY' named entity 'HUMAN' named entity 'MERS-COV' named entity 'IMPACT' named entity 'NEW' named entity 'FULLY' named entity 'DETAILED' named entity 'DIFFERENT' named entity 'THERAPEUTIC' named entity 'PREVENTION' named entity 'RAPID' named entity 'ABOUT' named entity 'BEING' named entity 'VACCINE' named entity 'IMMUNITY' named entity 'STRATEGIES'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software